Evidence map›Paper›PMID 36139489›Full record

ArticleCells2022

Ablation of Sphingosine Kinase 1 Protects Cornea from Neovascularization in a Mouse Corneal Injury Model.

Joseph L Wilkerson, Sandip K Basu, Megan A Stiles, Amanda Prislovsky, Richard C Grambergs, Sarah E Nicholas, Dimitrios Karamichos, Jeremy C Allegood, Richard L Proia, Nawajes Mandal

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Sphingolipids: drivers of cardiac fibrosis and atrial fibrillation.Journal of molecular medicine (Berlin, Germany) · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Joseph L WilkersonDean A. McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0003-4683-7589
Sandip K BasuDepartment of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA.
Megan A StilesDean A. McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Amanda PrislovskyDepartment of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA.
Richard C GrambergsDepartment of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA.
Sarah E NicholasNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Dimitrios KaramichosNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Jeremy C AllegoodDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
Richard L ProiaGenetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-0456-1270
Nawajes MandalDean A. McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0003-4489-7748
University of Tennessee Health Science Center · USUniversity of North Texas · USDean McGee Eye Institute · USNational Institutes of Health · USUniversity of Utah · USVirginia Commonwealth University · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
Ceramides and Sphingolipids as Predictors of Incident DysglycemiaR01DK128129 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DAGOGO-JACK, M.D., D.SC., SAMUEL, MANDAL, NAWAJES · 2021 to 2024
$2.0M
Sphingolipids and their Impact in Corneal Wound HealingR01EY031316 · NEI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI KARAMICHOS, DIMITRIOS, MANDAL, NAWAJES · 2020 to 2023
$1.8M
Sphingolipid Metabolism and Signaling in the RetinaR01EY022071 · NEI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MANDAL, NAWAJES · 2012 to 2016
$1.8M
Sphingolipid signaling in corneal wound healing and fibrosisR21EY025256 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI KARAMICHOS, DIMITRIOS, MANDAL, NAWAJES · 2015 to 2016
$429k
BLRD VA I01 BX004893NCI NIH HHS P30 CA016059NEI NIH HHS R01 EY022071NEI NIH HHS R01 EY031316NEI NIH HHS R21 EY025256NIDDK NIH HHS R01 DK128129
6 · The paper itself

Abstract

The purpose of this study was to investigate the role of sphingosine kinase 1 (SphK1), which generates sphingosine-1-phosphate (S1P), in corneal neovascularization (NV)

Indexed as

Corneal InjuriesSphingosineAnimalsCeramidesCorneaCytokinesDisease Models, AnimalLysophospholipidsMiceNeovascularization, PathologicPhosphotransferases (Alcohol Group Acceptor)Sodium HydroxideSphingolipidsSphingomyelinsSphingosine KinaseUridineCeramidesCytokinesLysophospholipidsPhosphotransferases (Alcohol Group Acceptor)Sodium HydroxideSphingolipidsSphingomyelinsSphingosinesphingosine 1-phosphateSphingosine KinaseUridinecorneaneovascularizationsphingolipidsphingosine-1-phosphatesphingosine kinase 1

Identifiers

PMID36139489
PMCPMC9497123
OpenAlexW4296252669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.